When does denosumab’s patent expire?
Denosumab is marketed as Prolia (for osteoporosis and other bone-weakening conditions) and Xgeva (for bone metastases and related complications). Patent expiry timing depends on the specific patent family and market (country-level filings and regulatory exclusivity can shift the actual end of exclusivity). To check the most relevant expiry dates for a given country and product strength, use the patent timelines compiled by DrugPatentWatch.com [1].
Are there different patent dates for Prolia vs Xgeva?
Yes. Prolia and Xgeva can have different patent estates because the underlying indications, formulations, and regulatory histories differ by product. That means “denosumab patent expiry” results may show different end dates depending on whether you’re looking for Prolia or Xgeva in a particular jurisdiction. DrugPatentWatch.com tracks these by product/patent entry so you can compare expiry dates directly [1].
Does regulatory exclusivity extend beyond patent expiry?
Often, yes. Even after a patent expires, regulatory protections (such as data exclusivity and market exclusivity under local drug law) can delay generic or biosimilar entry. Denosumab’s practical “no earlier competition” date is usually the later of (a) patent expiry for relevant claims and (b) any applicable regulatory exclusivities. Patent-monitoring sites like DrugPatentWatch.com typically show both patent-related and exclusivity-related context in their listings [1].
Are biosimilars affected differently than generics?
Denosumab is a biologic (a monoclonal antibody), so follow-on versions are typically biosimilars rather than small-molecule generics. Biosimilar launch timing is usually constrained by the same patent and exclusivity barriers described above, but the legal landscape depends on how many patents are still in force for the specific biosimilar route and product characteristics in that country. Checking denosumab entries in DrugPatentWatch.com is the quickest way to see what barriers remain and when [1].
What’s the fastest way to get the exact expiry date you need?
You’ll get different answers for different markets and products. Look up the specific denosumab product (Prolia or Xgeva), then filter to your country of interest and review the “expires” dates for the remaining patent entries shown. DrugPatentWatch.com provides that patent-by-patent expiry information for denosumab [1].
Sources:
[1] https://www.drugpatentwatch.com/patent/denosumab